The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti–CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC.
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Eisai; Entos; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Tempus; Totus Medicines
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Nicholas DeVito
Employment - Duke University
Stock and Other Ownership Interests - Corvus Pharmaceuticals (I)
Honoraria - AlphaSights Consulting; Gerson Lehrman Group
Research Funding - Astellas Pharma (Inst); Merck; Xilio Therapeutics (Inst)
 
Aparna Parikh
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Checkmate Pharmaceuticals; CVS; Delcath Systems; Foundation Medicine; Guardant Health; Illumina; KAHR Medical; Pfizer; Pfizer; PMV Pharma (I); SAGA Diagnostics; Scarce; Seagen; Sirtex Medical; Taiho Oncology; Takeda; Takeda; UpToDate; Value Analytics Labs; Xilio Therapeutics
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Erasca, Inc; Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); PMV Pharma; PureTech (Inst); Syndax
Travel, Accommodations, Expenses - Karkinos Healthcare; Karkinos Healthcare
Other Relationship - C2i genomics; CADEX Genomics; Parithera; Xact Robotics
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Hao Xie
Honoraria - Mayo Clinic CME
Research Funding - BioNTech SE (Inst); Cardiff Oncology (Inst); DynamiCure Biotechnology (Inst); Qurient Therapeutics (Inst); SparX Biopharmaceutical Corp (Inst); Xilio Therapeutics (Inst); Xilis (Inst)
Patents, Royalties, Other Intellectual Property - Patent application entitled "DEGRADERS OF SON OF SEVENLESS HOMOLOG 1" was filed with the United States Patent and Trademark Office on 8/11/2023.
 
Sandra Algaze
Consulting or Advisory Role - Elevar Therapeutics
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Jeremy Jones
No Relationships to Disclose
 
Cesar Perez
Consulting or Advisory Role - BeiGene; EMD Serono; Pfizer
Research Funding - Accutar Biotech (Inst); ADANATE Biotechnology (Inst); Artios (Inst); BeiGene (Inst); Coherent Biopharma (Inst); Compass Therapeutics (Inst); Corvus Pharmaceuticals (Inst); DualityBio (Inst); Elevation Oncology (Inst); Elpiscience (Inst); Genentech (Inst); Hyamab (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Loxo/Lilly (Inst); Merus (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst); Seagen (Inst); Systimmune (Inst); Tachyon Therapeutics (Inst); Tallac Therapeutics (Inst); Xilio Therapeutics (Inst); Zhuhai Yufan Biotechnologies (Inst)
 
Andrae Vandross
Employment - Next Oncology; Texas Oncology
Consulting or Advisory Role - Abbvie (Inst); Boxer Capital (Inst); NiKang Therapeutics (Inst); Pliant Pharma
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); BiOneCure (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); Deciphera (Inst); Exelixis (Inst); Gilead Sciences (Inst); Immunomedics (Inst); IMPAC Medical Systems (Inst); Kirilys Therapeutics (Inst); Kura Oncology (Inst); Lyvgen Biopharma (Inst); MBRACE (Inst); Medikine (Inst); Nanjing (Inst); Nested Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); OncoResponse (Inst); Pliant (Inst); PMV Pharma (Inst); Sirnaomics (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Vividion Therapeutics (Inst); Xilio Therapeutics (Inst); Yufan Biotechnologies (Inst); ZielBio (Inst); Zumutor Biologics (Inst)
 
Alberto Bessudo
Research Funding - Xilio Therapeutics
 
John Knecht
Research Funding - Xilio Therapeutics
 
Ekta Patel
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - MustangBio; Xilio Therapeutics
Patents, Royalties, Other Intellectual Property - Patents, TCR2, Mustang Bio
 
Damiano Fantini
Employment - Merck (I); Xilio Therapeutics
Stock and Other Ownership Interests - Lilly; Merck (I); Xilio Therapeutics
 
Scott McConnell
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
Consulting or Advisory Role - Xilio Therapeutics
Travel, Accommodations, Expenses - Xilio Therapeutics
 
Myra Popejoy
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Invivyd Inc; Merck; Xilio Therapeutics
 
Bruce Dezube
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Diwakar Davar
Stock and Other Ownership Interests - mBiomics; Zola
Honoraria - ACM Biolabs; Arcus Biosciences; Ascendis Pharma; Castle Biosciences; Clinical Care Options (CCO); Gerson Lehrman Group; GlaxoSmithKline; Immunocore; Medical Learning Group; Merck; Regeneron; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; MBQ Pharma; Revolution Medicines; Taiho Pharmaceutical; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)